Vertex Pharmaceuticals JOURNAVX 2026 Inflection: Why the Non-Opioid Pain Franchise Could Unlock 30% Upside in VRTX Stock
Vertex Pharmaceuticals (VRTX) at $451.63 trades at 20.9x forward earnings as JOURNAVX prescriptions surge, the CF franchise extends via ALYFTREK, and CASGEVY scales — base case fair value $580, 28% upside.